3-氨基-4-甲氧基苯甲酸乙酯 | 16357-44-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-4-甲氧基苯甲酸乙酯
• 中文别名: 3-氨基-4-甲基苯甲酸乙酯
• 英文名称: ethyl 3-amino-4-methoxybenzoate
• 英文别名: 3-amino-4-methoxy-benzoic acid ethyl ester；Ethyl-3-amino-4-methoxybenzoat；3-Amino-4-methoxy-benzoesaeure-aethylester；3-Amino-anissaeure-aethylester
• CAS: 16357-44-1
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: FEWCDEPEMGXGFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2922509090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319
• 储存条件：
  储存条件：2-8°C，避光，惰性气体环境中。

反应信息

• 作为反应物：
  描述：

  3-氨基-4-甲氧基苯甲酸乙酯 在 吡啶 、 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 6.0h， 生成
  参考文献：
  名称：

  Development of triarylsulfonamides as novel anti-inflammatory agents

  摘要：

  Triaylsulfonamides were identified as novel anti-inflammatory agents, acting by inhibition of RANKL and TNF alpha signaling. Structure-activity studies led to the identification of compounds with in vitro potencies of <100 nM against J774 macrophages and osteoclasts, but with little activity against osteoblasts or hepatocytes (IC50 >50 mu M). A representative compound (4k, ABD455) was able to completely prevent inflammation in vivo in a prevention model and was highly effective at controlling inflammation in a treatment model. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.067
• 作为产物：
  描述：

  ethyl 4-methoxy-3-nitrobenzoate 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 168.0h， 以81%的产率得到3-氨基-4-甲氧基苯甲酸乙酯
  参考文献：
  名称：

  对称二酯官能化 Tröger 碱基类似物的合成

  摘要：

  通过在芳环上加入给电子基团和/或提高苯胺单元的溶解度，酯官能化的 Troger 碱类似物的产率得到显着提高。除了 2,8-二酯化合物外，1,7-、3,9- 和 4,10-二酯官能化的 Troger 碱类似物也是首次制备。

  DOI：

  10.1002/ejoc.201000086

文献信息

• Syntheses of 3-acetoacetylaminobenzo[b]furan derivatives having cysteinyl leukotriene 2 receptor antagonistic activity
  作者：Kumiko Ando、Eriko Tsuji、Yuko Ando、Noriko Kuwata、Jun-ichi Kunitomo、Masayuki Yamashita、Shunsaku Ohta、Shigekatsu Kohno、Yoshitaka Ohishi

  DOI：10.1039/b312682j

  日期：——

  Novel 3-acetoacetylaminobenzo[b]furan derivatives having a modified triene system at the 3-position were synthesized starting with 3-aminobenzo[b]furans. The enol isomers, 3-[(3-hydroxybut-2-enonyl)amino]benzo[b]furans (), of the 3-acetoacetylaminobenzo[b]furans were obtained as stable isomers owing to formation of a hydrogen bonding between the enol hydroxyl group and the amidocarbonyl group. The

  从3-氨基苯并[b]呋喃开始，合成了在3-位具有修饰的三烯系统的新型3-乙酰乙酰氨基苯并[b]呋喃衍生物。由于3-烯丙基乙酰氨基苯并[b]呋喃之间形成氢键，因此作为稳定异构体获得了3-乙酰基乙酰氨基苯并[b]呋喃的烯醇异构体3-[（3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃。羟基和酰胺羰基。通过C-3侧链的C-2取代基的平面性表明烯醇化合物中存在改性的共轭三烯系统。评估了半胱氨酸白三烯1和2受体对这些化合物的拮抗活性。2-（4-氰基苯甲酰基或乙氧基羰基）-3-[（2-氰基-3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃（，）具有中等活性。
• [EN] HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS<br/>[FR] TRIAZOLES SUBSTITUÉS PAR HÉTÉROARYLE UTILISÉS EN TANT QU'AGONISTES DU RÉCEPTEUR APJ
  申请人：AMGEN INC

  公开号：WO2018097945A1

  公开（公告）日：2018-05-31

  Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  化合物的化学式（I）和化学式（II），其药用可接受盐，上述任何的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。化学式I和化学式II的化合物具有以下结构：其中变量的定义在此提供。
• LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN
  申请人：Petter Russell C.

  公开号：US20110269244A1

  公开（公告）日：2011-11-03

  The present invention relates to enzyme inhibitors. More specifically, the present invention relates to ligand-directed covalent modification of proteins; method of designing same; pharmaceutical formulation of same; and method of use.

  本发明涉及酶抑制剂。更具体地说，本发明涉及配体导向的蛋白共价修饰；相同设计方法；相同的药物配方；以及使用方法。
• Dye-forming coupler and silver halide color photographic light-sensitive material
  申请人：Takeuchi Kiyoshi

  公开号：US20050079456A1

  公开（公告）日：2005-04-14

  A dye-forming coupler and compound of formula (I): wherein Q represents a residue that forms, together with —N—C═N—, a nitrogen-containing 6-membered ring; R A represents an aryl, heterocyclic, or —(R 1 ) r —(R 4 ) m group; X represents an aryl group; Y represents a hydrogen atom, or a group capable of being split-off upon a coupling reaction with an oxidized product of a developing agent: wherein, when R A represents an —(R 1 ) r —(R 4 ) m group, R 1 represents a methylene group, a methine group, or a carbon atom; r is 1 to 30; R 4 represents a substituent except for a hydrogen atom; m is 1 to 30; and the —(R 1 ) r —(R 4 ) m group does not represent a straight-chain alkyl group.

  一种染料形成偶联剂和化合物的公式（I）：其中Q代表与—N—C═N—一起形成含氮6元环的残基；RA代表芳基，杂环或—（R1）r—（R4）m基团；X代表芳基基团；Y代表氢原子或能够在偶联反应中与氧化的显影剂产生分裂的基团：其中，当RA代表—（R1）r—（R4）m基团时，R1代表亚甲基基团，亚胺基团或碳原子；r为1到30；R4代表除氢原子外的取代基；m为1到30；且—（R1）r—（R4）m基团不代表直链烷基。
• Nitrogen-containing heterocyclic compounds and benzamide compounds and drugs containing the same
  申请人：——

  公开号：US20040224959A1

  公开（公告）日：2004-11-11

  Disclosed are compounds represented by formula (I) which have triglyceride biosynthesis inhibitory activity in the liver and inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein from the liver and particularly have excellent inhibitory activity against the secretion of apolipoprotein B-containing lipoprotein, are free from side effect of accumulation of lipids in the liver, and are useful for the treatment and prevention of hyperlipidemia and arteriosclerotic diseases. In formula (I), R 1 and R 2 represent alkyl, alkoxy, cycloalkyl, phenyl, alkenyl, alkynyl, or a five- or six-membered saturated or unsaturated heterocyclic ring, or R 1 and R 2 , together with a nitrogen atom to which R 1 and R 2 are attached, may form a ring; R 3 and R 4 represent a hydrogen atom, alkyl, a halogen atom, hydroxyl, nitrile, alkoxycarbonyl, alkoxy, or carboxyl; or R 2 and R 3 may be attached to each other to form —(CH 2 ) m —, —N═CH—, —CH═N—, or —(C 1-6 alkyl)C═N—; A, D, E, and G each represent a carbon atom, or any one of A, D, E, and G represents a nitrogen atom with the other three each representing a carbon atom; Q represents a nitrogen atom or a carbon atom; Y represents a group represented by formula (II) wherein X represents a hydrogen atom, group —C(═O)N(R 5 )R 6 or group —C(═O)OR 7 , R 8 is absent or represents a bond, an oxygen atom, a sulfur atom, —SO 2 —, —SO—, —CH 2 —CH 2 —, or —CH═CH—, and R 9 and R 10 represent a hydrogen atom, alkyl, alkoxy, a halogen atom, or hydroxyl; and Z represents —(CH 2 ) n —, —O—(CH 2 ) i —, or —C(═O)NH—(CH 2 ) i —. 1

  本发明涉及一种由公式（I）表示的化合物，其在肝脏中具有三酰甘油生物合成抑制活性和抑制含载脂蛋白B的脂蛋白从肝脏分泌的活性，特别是对含载脂蛋白B的脂蛋白的分泌具有出色的抑制活性，且不会出现在肝脏中积累脂质的副作用，对于治疗和预防高脂血症和动脉粥样硬化疾病非常有用。在公式（I）中，R1和R2代表烷基、烷氧基、环烷基、苯基、烯基、炔基或五元或六元饱和或不饱和杂环环，或R1和R2与R1和R2附着的氮原子一起形成环; R3和R4代表氢原子、烷基、卤素原子、羟基、腈、烷氧羰基、烷氧基或羧基; 或R2和R3可以相互附着以形成-（CH2）m-、-N═CH-、-CH═N-或-（C1-6烷基）C═N-; A、D、E和G每个代表一个碳原子，或任何一个A、D、E和G代表一个氮原子，其他三个代表一个碳原子; Q代表一个氮原子或一个碳原子; Y代表由公式（II）表示的基团，其中X代表氢原子、基团-C(═O)N(R5)R6或基团-C(═O)OR7，R8不存在或代表一个键，一个氧原子，一个硫原子，-SO2-，-SO-，-CH2-CH2-或-CH═CH-，R9和R10代表氢原子、烷基、烷氧基、卤素原子或羟基; Z代表-（CH2）n-、-O-（CH2）i-或-C(═O)NH-（CH2）i-。